Advertisement

Risk factors for opportunistic infections in infliximab-treated patients: the importance of screening in prevention

  • C. Garcia-VidalEmail author
  • S. Rodríguez-Fernández
  • S. Teijón
  • M. Esteve
  • M. Rodríguez-Carballeira
  • J. M. Lacasa
  • G. Salvador
  • J. Garau
Article

Abstract

We sought to determine factors associated with opportunistic infections (OI) in infliximab-treated patients. A retrospective study cohort (1999–2004) was examined. Nine OI were diagnosed in 94 infliximab-treated patients: tuberculosis (four), visceral leishmaniasis (one), pyogenic muscular abscess (one Salmonella spp. and one Streptococcus pneumoniae), and two viral infections (hepatitis B virus [HBV] and zoster ophthalmicus). The risk for OI was significantly higher in the first year of treatment (odds ratio [OR] 8; 95% confidence interval [CI] 2–50). Previous treatment with more than two immunosuppressive drugs was the only factor related to OI (OR 8.686; 95% CI 1.889–39.943). We identified the subset of patients treated with infliximab who had a higher risk for OI. The screening of latent infections is key to diminishing the incidence of these infections.

Keywords

Infliximab Opportunistic Infection Connective Tissue Disease Visceral Leishmaniasis Invasive Aspergillosis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgment

Part of these results have been presented previously at the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, 27–30 September 2006, San Francisco, CA. We thank David García-Cortés for his value technical assistance.

References

  1. 1.
    Wallis RS, Broder MS, Wong JY (2004) Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 38:1261–1265. doi: 10.1086/383317 PubMedCrossRefGoogle Scholar
  2. 2.
    Keane J, Gershon S, Wise RP et al (2001) Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345:1098–1104. doi: 10.1056/NEJMoa011110 PubMedCrossRefGoogle Scholar
  3. 3.
    Crum NF, Lederman ER, Wallace MR (2005) Infections associated with tumor necrosis factor-alpha antagonists. Medicine (Baltimore) 84:291–302. doi: 10.1097/01.md.0000180044.19285.9a CrossRefGoogle Scholar
  4. 4.
    Doran MF, Crowson CS, Pond GR et al (2002) Predictors of infection in rheumatoid arthritis. Arthritis Rheum 46:2294–2300. doi: 10.1002/art.10529 PubMedCrossRefGoogle Scholar
  5. 5.
    Greenberg SB (2002) Infections in the immunocompromised rheumatologic patient. Crit Care Clin 18:931–956. doi: 10.1016/S0749-0704(02)00022-2 PubMedCrossRefGoogle Scholar
  6. 6.
    Cunnane G, Doran M, Bresnihan B (2003) Infections and biological therapy in rheumatoid arthritis. Best Pract Res Clin Rheumatol 17:345–363. doi: 10.1016/S1521-6942(02)00107-9 PubMedCrossRefGoogle Scholar
  7. 7.
    Garcia-Vidal C, Salavert M (2007) Artritis reumatoide y el tropismo infeccioso. Seminarios Fundacion Esp Reumatologia 8:68–87CrossRefGoogle Scholar
  8. 8.
    Elkayam O, Caspi D, Reitblatt T et al (2004) The effect of tumor necrosis factor blockade on the response to pneumococcal vaccination in patients with rheumatoid arthritis and ankylosing spondylitis. Semin Arthritis Rheum 33:283–288. doi: 10.1053/j.semarthrit.2003.10.003 PubMedCrossRefGoogle Scholar
  9. 9.
    Fomin I, Caspi D, Lavy V et al (2006) Vaccination against influenza in rheumatoid arthritis: the effect of disease modifying drugs, including TNF alpha blockers. Ann Rheum Dis 65:191–194. doi: 10.1136/ard.2005.036434 PubMedCrossRefGoogle Scholar
  10. 10.
    Visvanathan S, Keenan GF, Baker DG et al (2007) Response to pneumococcal vaccine in patients with early rheumatoid arthritis receiving Infliximab plus methotrexate or methotrexate alone. J Rheumatol 34:952–957PubMedGoogle Scholar
  11. 11.
    Gelinck LB, van der Bijl AE, Visser LG et al (2008) Synergistic immunosuppressive effect of anti-TNF combined with methotrexate on antibody responses to the 23 valent pneumococcal polysaccharide vaccine. Vaccine 26:3528–3533. doi: 10.1016/j.vaccine.2008.04.028 PubMedCrossRefGoogle Scholar
  12. 12.
    Bergstrom L, Yocum DE, Ampel NM et al (2004) Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor alpha antagonists. Arthritis Rheum 50:1959–1966. doi: 10.1002/art.20454 PubMedCrossRefGoogle Scholar
  13. 13.
    Gardam MA, Keystone EC, Menzies R et al (2003) Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis 3:148–155. doi: 10.1016/S1473-3099(03)00545-0 PubMedCrossRefGoogle Scholar
  14. 14.
    Mow WS, Abreu-Martin MT, Papadakis KA et al (2004) High incidence of anergy in inflammatory bowel disease patients limits the usefulness of PPD screening before infliximab therapy. Clin Gastroenterol Hepatol 2:309–313. doi: 10.1016/S1542-3565(04)00060-6 PubMedCrossRefGoogle Scholar
  15. 15.
    Carmona L, Gómez-Reino JJ, Rodríguez-Valverde V et al (2005) Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 52:1766–1772. doi: 10.1002/art.21043 PubMedCrossRefGoogle Scholar
  16. 16.
    Sellam J, Hamdi H, Roy C et al (2007) Comparison of in vitro-specific blood tests with tuberculin skin test for diagnosis of latent tuberculosis before anti-TNF therapy. Ann Rheum Dis 66:1610–1615. doi: 10.1136/ard.2007.069799 PubMedCrossRefGoogle Scholar
  17. 17.
    Mazurek GH, Weis SE, Moonan PK et al (2007) Prospective comparison of the tuberculin skin test and 2 whole-blood interferon-gamma release assays in persons with suspected tuberculosis. Clin Infect Dis 45:837–845. doi: 10.1086/521107 PubMedCrossRefGoogle Scholar
  18. 18.
    Mazurek GH, Zajdowicz MJ, Hankinson AL et al (2007) Detection of Mycobacterium tuberculosis infection in United States navy recruits using the tuberculin skin test or whole-blood interferon-gamma release assays. Clin Infect Dis 45:826–836. doi: 10.1086/521106 PubMedCrossRefGoogle Scholar
  19. 19.
    Esteve M, Saro C, González-Huix F et al (2004) Chronic hepatitis B reactivation following infliximab therapy in Crohn’s disease patients: need for primary prophylaxis. Gut 53:1363–1365. doi: 10.1136/gut.2004.040675 PubMedCrossRefGoogle Scholar
  20. 20.
    Esteve M, Loras C, González-Huix F (2007) Lamivudine resistance and exacerbation of hepatitis B in infliximab-treated Crohn’s disease patient. Inflamm Bowel Dis 13:1450–1451. doi: 10.1002/ibd.20202 PubMedCrossRefGoogle Scholar
  21. 21.
    Garcia Vidal C, Rodríguez Fernández S, Martínez Lacasa J et al (2005) Paradoxical response to antituberculous therapy in infliximab-treated patients with disseminated tuberculosis. Clin Infect Dis 40:756–759. doi: 10.1086/427941 PubMedCrossRefGoogle Scholar
  22. 22.
    Tubach F, Ravaud P, Salmon-Céron D et al (2006) Emergence of Legionella pneumophila pneumonia in patients receiving tumor necrosis factor-alpha antagonist. Clin Infect Dis 43:e95–e100. doi: 10.1086/508538 PubMedCrossRefGoogle Scholar
  23. 23.
    Dixon WG, Watson K, Lunt M et al (2006) Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 54:2368–2376. doi: 10.1002/art.21978 PubMedCrossRefGoogle Scholar
  24. 24.
    Hine RJ, Everson MP, Hardin JM et al (1990) Methotrexate therapy in rheumatoid arthritis patients diminishes lectin-induced mononuclear cell proliferation. Rheumatol Int 10:165–169. doi: 10.1007/BF02274842 PubMedCrossRefGoogle Scholar
  25. 25.
    Lionakis MS, Kontoyiannis DP (2003) Glucocorticoids and invasive fungal infections. Lancet 362:1828–1838. doi: 10.1016/S0140-6736(03)14904-5 PubMedCrossRefGoogle Scholar
  26. 26.
    McCune WJ, Golbus J, Zeldes W et al (1988) Clinical and immunologic effects of monthly administration of intravenous cyclophosphamide in severe systemic lupus erythematosus. N Engl J Med 318:1423–1431PubMedGoogle Scholar
  27. 27.
    Schreiber SL, Crabtree GR (1992) The mechanism of action of cyclosporin A and FK506. Immunol Today 13:136–142. doi: 10.1016/0167-5699(92)90111-J PubMedCrossRefGoogle Scholar
  28. 28.
    Jick SS, Lieberman ES, Rahman MU et al (2006) Glucocorticoid use, other associated factors, and the risk of tuberculosis. Arthritis Rheum 55:19–26. doi: 10.1002/art.21705 PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  • C. Garcia-Vidal
    • 1
    • 4
    Email author
  • S. Rodríguez-Fernández
    • 1
  • S. Teijón
    • 1
  • M. Esteve
    • 2
  • M. Rodríguez-Carballeira
    • 1
  • J. M. Lacasa
    • 1
  • G. Salvador
    • 3
  • J. Garau
    • 1
  1. 1.Service of Internal MedicineHospital Mútua de Terrassa, University of BarcelonaBarcelonaSpain
  2. 2.Service of GastroenterologyHospital Mútua de Terrassa, University of BarcelonaBarcelonaSpain
  3. 3.Service of RheumatologyHospital Mútua de Terrassa, University of BarcelonaBarcelonaSpain
  4. 4.Infectious Disease ServiceHospital Universitari de BellvitgeBarcelonaSpain

Personalised recommendations